In an attempt to further improve the immune stimulatory properties of Dexo and to provide a vaccination tool easily transferrable to clinical development for both infectious diseases and cancer, we compared poly(I:C) (a TLR-3 ligand) and CpG-B (a TLR-9 ligand) to LPS as adjuvants for DC maturation during Dexo production23, 24, 25, 26, 27, 28. Here, TLR9 is linked to cancer.